Neocor JSC doubles bioprosthetic heart valve production with new Kemerovo plant

Neocor JSC has opened a new bioprosthetic heart valve plant in Kemerovo. The facility will double the company's production capacity, increasing annual output from 2,000 to 4,500 units. Funding for the project came from multiple sources, including state-backed loans and regional investment funds. The construction of the manufacturing site received 80 million rubles from SME Bank. An additional 90 million rubles came as a subsidised loan from Russia's Industry Development Fund (IDF). The Kuzbass Industrial Development Fund also contributed 10 million rubles to the project.

In total, the plant required an investment of 346 million rubles. This funding allowed Neocor to move from rented premises into its own purpose-built complex. The company specialises in bioprosthetic heart valves, annuloplasty rings, cardiovascular patches, and vascular bioprostheses. With expanded capacity, Neocor aims to meet growing domestic demand while increasing exports. By 2027, the company plans to enter five new markets beyond Russia and India, targeting the UAE, Saudi Arabia, Kazakhstan, Belarus, and Turkey. It also intends to start producing transcatheter heart valves derived from animal tissues within the same timeframe.

The new Kemerovo facility will strengthen Neocor's position in the medical device sector. Higher production volumes will support both local healthcare needs and international sales. The company's expansion aligns with its goal of introducing advanced cardiovascular products by the end of the decade.